Myfortic 180 mg / 360 mg TABLETS
PDF Leaflet Revision Date: 17 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of acute transplant rejection in renal transplant patients.
Dosage (summary)
720 mg twice daily (1,440 mg total).
Special Populations
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; teratogenic effects noted.
Key Drug Interactions
- Azathioprine
- Live vaccines
- Antacids with magnesium and aluminium hydroxides
Contraindications
- Hypersensitivity to mycophenolate
- Pregnancy
- Lactation
- Women of childbearing potential not using contraception
Common side effects
- Leucopenia
- Diarrhoea
- Hypertension
- Fatigue
Counselling Points
- Use effective contraception
- Report signs of infection
- Avoid live vaccines
Serious warnings
- Risk of infections and malignancy
- Teratogenicity
- Progressive multifocal leukoencephalopathy (PML)
Important Disclaimer
The Myfortic 180 mg / 360 mg TABLETS professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
